Several antiarrhythmic and rate-control agents used for atrial fibrillation contain IK1-blocking agents [115], while blockers of atrial-specific potassium channels (Ca2 + -activated K+ channels of small conductance, SK channels) have been suggested as future therapeutic drugs [116,117]. Here, KCNA3 is linked to atrial fibrillation.